Vav3 regulates osteoclast function and bone mass

Abstract

Osteoporosis, a leading cause of morbidity in the elderly, is characterized by progressive loss of bone mass resulting from excess osteoclastic bone resorption relative to osteoblastic bone formation. Here we identify Vav3, a Rho family guanine nucleotide exchange factor, as essential for stimulated osteoclast activation and bone density in vivo. Vav3-deficient osteoclasts show defective actin cytoskeleton organization, polarization, spreading and resorptive activity resulting from impaired signaling downstream of the M-CSF receptor and αvβ3 integrin. Vav3-deficient mice have increased bone mass and are protected from bone loss induced by systemic bone resorption stimuli such as parathyroid hormone or RANKL. Moreover, we provide genetic and biochemical evidence for the role of Syk tyrosine kinase as a crucial upstream regulator of Vav3 in osteoclasts. Thus, Vav3 is a potential new target for antiosteoporosis therapy.

DOI: 10.1038/nm1194
0100200'06'07'08'09'10'11'12'13'14'15'16'17
Citations per Year

1,043 Citations

Semantic Scholar estimates that this publication has 1,043 citations based on the available data.

See our FAQ for additional information.

Cite this paper

@article{Faccio2005Vav3RO, title={Vav3 regulates osteoclast function and bone mass}, author={Roberta Faccio and Steven L Teitelbaum and Keiko Fujikawa and Jean C. Chappel and Alberta Zambonin Zallone and Victor L. J. Tybulewicz and Frederick P. Ross and Wojciech Swat}, journal={Nature Medicine}, year={2005}, volume={11}, pages={284-290} }